COMPANY UPDATES
04
Oct
2018
Novoheart Showcase at Annual Safety Pharmacology Society Meeting

Our latest technologies were widely showcased at the SPS Annual Meeting, held between Sep 30 to Oct 3, an industry conference attended by many decision-makers in the safety pharmacology space, both from pharma and the US Food & Drug Administration (FDA), in oral presentations, scientific posters and a brand new modular bioreactor display at our exhibition booth.

24
Sep
2018
Novoheart Recruits Notable Pharma Industry Executive, Bernard Fermini, Ph.D. as Chief R&D Officer

Novoheart is proud to announce today that it has appointed Bernard Fermini, Ph.D. as Chief Research & Development Officer. With his well-recognized stature in the safety pharmacology community, the addition of Dr. Fermini to the team further validates Novoheart's revolutionary technology to prospective clients who are seeking to implement it into their drug discovery and screening processes.

12
Sep
2018
Novoheart is selected as one of "The Top 50 of Innovative Biotechnology Enterprises in Guangdong-Hong Kong-Macau Greater Bay Area 2018 “

Novoheart is proud to announce that we have been successfully selected as one of "The Top 50 of Innovative Biotechnology Enterprises in Guangdong-Hong Kong-Macau Greater Bay Area 2018" , as one of 5 enterprises from Hong Kong on the list.

01
Aug
2018
Novoheart Appoints Biotech Industry Specialist as New Senior VP to Lead Commercial Development

We are pleased to announce Dr. Bill A. Williams is joining Novoheart today as Senior Vice President, Commercial Operations. With over 20 years of experience as a senior technical sales and business development executive in the biotechnology sector, Dr. Williams comes to Novoheart as a highly influential leader in the life science industry.

Subscribe To Our Newsletter

Fill out the following to subscribe and start receiving updates from us!